 Bellerophon Therapeutics, Inc. BLPH, a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the submission of an Investigational New Drug IND application to the U.S. Food and Drug Administration FDA to study the INOpulse inhaled nitric oxide system iNO for the treatment of patients infected with COVID-19. INOpulse is the only therapy to deliver targeted nitric oxide by autonomously adjusting to the patients breathing pattern to ensure accurate and consistent drug delivery into the airways. The proposed randomized, open-label study, called PULSE-CVD19-001, will evaluate the efficacy and safety of INOpulse in patients with COVID-19 who require supplemental oxygen. 